Step counts may predict outcomes in prostate cancer patients
NCT ID NCT06660862
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study looks at whether daily step counts can be used as a simple way to track how well vulnerable patients with advanced prostate cancer are doing on a combination of darolutamide and standard hormone therapy. About 80 adults who are frail or have other health issues will wear a device to measure their steps over 6 months. The goal is to see if changes in step counts relate to side effects, quality of life, and overall treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
o University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.